ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2015
Adverse breast cancer treatment effects: the economic case for making rehabilitative programs standard of care.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- What are the economic burden and costs associated with the treatment of breast cancer-related lymphoedema? A systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Pooled it
- Do complementary and integrative medicine therapies reduce healthcare utilization among oncology patients? A systematic review of the literature and recommendations.European journal of oncology nursing : the official journal of European Oncology Nursing Society · 2018Pooled it
- Breast cancer-related lymphedema and its treatment: how big is the financial impact?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Trial
- A Randomized Clinical Trial Comparing the Impact of a Web-Based Multimedia Intervention Versus an Educational Pamphlet on Patient Outcomes in Breast Cancer Survivors with Chronic Secondary Lymphedema.Journal of women's health (2002) · 2020Trial
- Trial
- A phenomenological study of women with breast cancer-related lymphedema using the healthcare system.The British journal of occupational therapy · 2025Article
- Article
- Upper Limb Morbidity in Newly Diagnosed Individuals After Unilateral Surgery for Breast Cancer: Baseline Results from the AMBER Cohort Study.Annals of surgical oncology · 2023Article
- Advances in the Properties of Incomptine A: Cytotoxic Activity and Downregulation of Hexokinase II in Breast Cancer Cell Lines.International journal of molecular sciences · 2023Article
- Side effect prediction based on drug-induced gene expression profiles and random forest with iterative feature selection.The pharmacogenomics journal · 2021Article
- Patient and Medical Oncologists' Perspectives on Prescribed Lifestyle Intervention-Experiences of Women with Breast Cancer and Providers.Journal of clinical medicine · 2020Article
- Lymphedema Signs, Symptoms, and Diagnosis in Women Who Are in Minority and Low-Income Groups and Have Survived Breast Cancer.Physical therapy · 2020Observational
- Psychosocial Issues Associated with Breast Cancer-Related Lymphedema: a Literature Review.Current breast cancer reports · 2020Review
- Examining Obesity in Lymphedema: A Retrospective Study of 178 New Patients with Suspected Lymphedema at a Canadian Hospital-Based Clinic.Physiotherapy Canada. Physiotherapie Canada · 2020Article
- Drivers of cost differences between US breast cancer survivors with or without lymphedema.Journal of cancer survivorship : research and practice · 2019Article
- Downregulation of miR-505 promotes cell proliferation, migration and invasion, and predicts poor prognosis in breast cancer.Oncology letters · 2019Article
- Observational
- "It still affects our economic situation": long-term economic burden of breast cancer and lymphedema.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Article
- Long-term out of pocket expenditure of people with cancer: comparing health service cost and use for indigenous and non-indigenous people with cancer in Australia.International journal for equity in health · 2019Article
- Consumer credit as a novel marker for economic burden and health after cancer in a diverse population of breast cancer survivors in the USA.Journal of cancer survivorship : research and practice · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this work was to evaluate the patient-borne financial cost of common, adverse breast cancer treatment-associated effects, comparing cost across women with or without these side effects.
methodsTwo hundred eighty-seven Australian women diagnosed with early-stage breast cancer were prospectively followed starting at 6 months post-surgery for 12 months, with three monthly assessments of detailed treatment-related side effects and their direct and indirect patient costs attributable to breast cancer. Bootstrapping statistics were used to analyze cost data, and adjusted logistic regression was used to evaluate the association between costs and adverse events from breast cancer. Costs were inflated and converted from 2002 Australian to 2014 US dollars.
resultsMore than 90 % of women experienced at least one adverse effect (i.e., post-surgical issue, reaction to radiotherapy, upper-body symptoms or reduced function, lymphedema, fatigue, or weight gain). On average, women paid $5,636 (95 % confidence interval (CI), $4,694, $6,577) in total costs. Women with any one of the following symptoms (fatigue, reduced upper-body function, upper-body symptoms) or women who report ≥4 adverse treatment-related effects, have 1.5 to nearly 4 times the odds of having higher healthcare costs than women who do not report these complaints (p < 0.05).
conclusionsWomen face substantial economic burden due to a range of treatment-related health problems, which may persist beyond the treatment period. Improving breast cancer care by incorporating prospective surveillance of treatment-related side effects and strategies for prevention and treatment of concerns (e.g., exercise) has real potential for reducing patient-borne costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.